WO2006127057A1 - Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel - Google Patents

Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel Download PDF

Info

Publication number
WO2006127057A1
WO2006127057A1 PCT/US2006/002185 US2006002185W WO2006127057A1 WO 2006127057 A1 WO2006127057 A1 WO 2006127057A1 US 2006002185 W US2006002185 W US 2006002185W WO 2006127057 A1 WO2006127057 A1 WO 2006127057A1
Authority
WO
WIPO (PCT)
Prior art keywords
estrogen
androgen
female
sexual dysfunction
vaginal
Prior art date
Application number
PCT/US2006/002185
Other languages
English (en)
Inventor
John W. Lyle
Original Assignee
Lyle Corporate Drvelopment, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyle Corporate Drvelopment, Inc. filed Critical Lyle Corporate Drvelopment, Inc.
Publication of WO2006127057A1 publication Critical patent/WO2006127057A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Definitions

  • This invention relates generally to methods and pharmaceutical formulations for treating female sexual dysfunction, and more particularly relates to the acute, non-systemic administration of an estrogen and/or androgen to the vaginal, vulvar and/or urethral area of a female patient, in need of such treatment.
  • the invention further relates to methods of using the present pharmaceutical formulations, including, but not limited to, the improved vaginal cell health as determined by vaginal tissue blood flow, regeneration of vaginal cells, and number of healthy vaginal cells present.
  • the present invention is directed to a new, highly effective non-systemic method of treating sexual dysfunction in women.
  • the method involves an acute administration of a pharmaceutical formulation to the vaginal, vulvar and/or urethral area of a female containing an estrogen and androgen or the like.
  • U.S. Patent No. 5,460,820 to Ebert et al. discloses a method of providing testosterone replacement therapy to a woman in need of such therapy comprising applying a testosterone-delivering patch.
  • U.S. Pat. Nos. 5,565,466 to Gioco et al., 5,731,339 to Lowrey, and 5,773,457 to Nahoum pertain to methods for modulating the human sexual response, with the Gioco et al. and Lowrey patents emphasizing the utility of phentolamine as an active agent.
  • U.S. Patent No. 5,877,216 to Place et al. discloses methods and formulations for treating female sexual dysfunction using a pharmaceutical formulation containing " selective vasodilating agents and the co-administration of testosterone to the vaginal area of the patient.
  • U.S Patent No. 6,395,744 to Adams et al. describes a method of treating sexual dysfunction in a female by stimulating peripheral pelvic nerve release of nitric oxide.
  • The- preferred compound for the method described therein is apomorphine, with or without a potentiating amount of an androgen compound.
  • U.S. Patent No. 6,294,550 to Place et al. describes a method and formulations for treating female sexual dysfunction using selected vasoactive agents administered to the vaginal area of the patient undergoing treatment.
  • U.S. Patent No. 6,306,841 to Place et al. discloses methods and formulations for the treatment of female sexual dysfunction using selected vasoactive agents administered to the vaginal area of the patient undergoing treatment.
  • U.S. Patent No. 6,756,407 to Heaton et al. discloses a method of treating sexual dysfunction in females by stimulating peripheral nerve release of nitric oxide. The method comprises the administration of apomorphine alone or with an apomorphine potentiating amount of an androgen.
  • hormone replacement therapy i.e. estrogen and progestin to replace the hormones lost at menopause
  • hormone replacement therapy side effects cause a 26% risk of invasive breast cancer, 41% risk of having a stroke, a 100% risk of blood clots, and a 29% risk of heart attack.
  • Testosterone administered as tablets, injection, implanted pellet, or skin patch may produce side effects such as, masculinisation with acne and excess body hair, scalp hair loss, fluid retention, deepening of the voice, enlargement of the clitoris and adverse effects on blood cholesterol. Further, systemic use of vasodialators in the treatment of sexual dysfunction have reported side effects of headache, nausea, facial flushing, diarrhea and potentially fatal drug interactions.
  • the present invention provides a method of treating a female patient exhibiting one or more symptoms associated with a condition of sexual dysfunction and who is not receiving chronic hormonal therapy.
  • the present invention is a method of treating sexual dysfunction in a human female which comprises administering directly to the vaginal tissue of a human female exhibiting one or more symptoms associated with a condition of sexual dysfunction and who is not receiving chronic hormonal therapy, prior to the
  • an effective sexual dysfunction treatment amount of a composition comprising at least one hormone selected from the group consisting of estrogen and androgen and/or pharmaceutically acceptable salt and ester thereof.
  • the method comprises administering directly to the vaginal tissue, prior to the female engaging in sexual intercourse, an effective non-systemic sexual dysfunction treatment amount of a composition comprising at least one hormone selected from the group consisting of estrogen and androgen and/or pharmaceutically acceptable salt or ester thereof, wherein said non-systemic amount does not enter the blood stream of the female.
  • the method comprises administering on an acute administrative basis directly to the vaginal tissue, prior to the female engaging in sexual intercourse, an effective non-systemic sexual dysfunction treatment amount of a composition comprising at least one hormone selected from the group consisting of estrogen and androgen and/or pharmaceutically acceptable salt or ester thereof, wherein said acute administrative basis comprises administering said amount directly to the vaginal tissue of the female, from about 5 minutes to about 6 hours, before the female engages in sexual intercourse.
  • the composition further comprises an effective amount of a vasodilating agent.
  • a method of promoting vaginal cell health, enhancing vaginal lubrication, and minimizing sexual problems resulting from vaginal cell hypoxia, involving vaginal vulvar administration of a composition comprising a pharmaceutical formulation containing a selected estrogen and/or androgen agent, in combination with a pharmaceutically acceptable vehicle.
  • the claimed method further comprises the use of a water-soluble lubricant.
  • a method for the treatment a female patient in need of such treatment exhibiting one or more symptoms associated with a condition of sexual dysfunction and who is not receiving chronic hormonal therapy which comprises applying an sexual dysfunctional treatment amount of a pharmaceutical formulation comprising at least one hormone selected from the group consisting of an estrogen and androgen and/or pharmaceutically acceptable salt or ester thereof, directly to the vaginal tissue of the female patient, prior to the female engaging in sexual intercourse, such that sexual dysfunction is treated.
  • administering refers to the manner in which a drug is presented to a subject. Administration can be accomplished by various routes well- known in the art, however, as contemplated herein, non-oral methods, such as topical application is the preferred method.
  • acute as used herein is for short-term administration of the formulations described herein. Short-term, or acute, administration is carried out prior to engagement in sexual intercourse. Alternately stated, acute administration is the application of the formulations described herein minutes to hours prior to the act of sexual intercourse. Conversely, long-term or chronic administration would be carried out for a period of at least three days to a week to many weeks, months, or even years. In preferred embodiments, the inventive formulations are administered on an acute basis prior to sexual intercourse.
  • “Androgenic steroid,” or “androgen,” refer to a steroid, natural or synthetic, which exerts its biological or pharmacological action primarily by binding to androgen receptors. Examples include, but are not limited to: testosterone, methyltestosterone, androstenedione, adrenosterone, dehydroepiandrosterone, oxymetholone, fluoxymesterone, methandrostenolone, testolactone, pregnenolone, 17 ⁇ - methylnortestosterone, norethandrolone, dihydrotestosterone, danazol, androsterone, nandrolone, stanozolol, ethylestrenol, oxandrolone, bolasterone, mesterolone, testosterone propionate, testosterone cypionate, testosterone phenylacetate, and testosterone enanthate, testosterone acetate, testosterone buciclate, testosterone heptanoate, testosterone decano
  • Coadministration refers to administration of multiple substances to one individual, either simultaneously or sequentially.
  • estrogen and androgen the term includes any situation in which women are receiving non-oral estrogen and non-oral androgen.
  • Estrogen and “estrogenic hormone” refer to any substance, natural or synthetic, that exerts a biological or pharmacological action primarily by binding to estrogen receptors. Examples include but are not limited to: 17- ⁇ -estradiol, 17- ⁇ - estradiol, estriol, estrone, and phytoestrogens. These estrogens may be derivatized or modified to form, for example, conjugated equine estrogens, esterified estrogens, ethinyl estradiol, etc.
  • esterified estrogens include but are not limited to: estradiol- 3,17-diacetate, estradiol-3 -acetate, estradiol- 17-acetate, estradiol-3,17-divalerate, estradiol-3 -valerate, estradiol- 17-valerate.
  • the estrogens may also be present as salts, (e.g.,as sodium estrogen sulfate), isomers, or prodrugs.
  • phytoestrogens which are plant-derived estrogens.
  • Isoflavones are one major form of phytoestrogen and have a common diphenolic structure that resembles the structure of potent synthetic estrogens such as diethylstilbesterol and hexestrol.
  • Major isoflavones found in humans include, but are not limited to genistein, diadzein, and equol.
  • an effective amount is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which may be used to produce a favorable change in the symptomology, disease or condition treated, whether that change is a decrease in or reversal of the effects of symptomology or disease state depending upon the disease state or condition treated.
  • an effective amount is that amount which is used to treat the symptomology associated with sexual dysfunction.
  • An effective amount for purposes of treating one or more symptoms of the present invention includes the non- systemic manner in which an active compound is administered to a patient.
  • composition is used interchangeably herein.
  • pharmaceutical and “drug” are also used interchangeably to refer to a pharmacologically active substance or composition. These terms of art are well-known in the pharmaceutical and medicinal arts.
  • Improved vaginal cell health refers to reducing, improving, or preventing the incidence and/or intensity of symptoms associated with estrogenic or androgenic steroid deficiency of the vaginal tissue.
  • symptoms include but are not limited to: sexual dysfunction, which can manifest in loss of sexual desire, decreased sensitivity to sexual stimulation, decreased arousability and capacity for orgasm, diminished vital energy, depressed mood, diminished sense of well-being, increased shyness, loss of muscle mass and function, and a combination thereof.
  • evaluations may be employed for measuring the achievement of desired effects in the case of androgen and estrogen delivery to the vaginal cells, which are well known in the art. Such evaluations may be performed by a physician, or other qualified medical personnel, and may include physical examination, blood tests, tissue samples and histological examination.
  • “Local administration” means administration by a non-systemic route at or in the vicinity of the site of an affliction, disorder or complication.
  • menopause is used throughout the specification to describe the period in a human female's life between the ages of approximately 45 and 50 after which menstruation (menses) naturally ceases.
  • the symptomology associated with menopause which is particularly relevant to the present invention includes bone loss associated with osteoporosis and most importantly, vaginal dyspareunia.
  • non-systemic refers to local administration such that the compound being administered does not significantly enter the blood stream.
  • systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration of a compound that provides a significant blood level.
  • topical administration is meant non-systemic administration and includes the application of the compounds of the invention externally to the epidermis and instillation of such a compound into the vagina of a female, and where it does not significantly enter the blood stream.
  • “Testosterone” refers to the compound having the IUPAC names (17 ⁇ )- 17-Hydroxyandrost-4-en-3-one, and ⁇ 4 -androsten-17 ⁇ -ol-3-one, as well as their isomers. Testosterone is listed in the Merck Index, entry no. 9322, at page 1569, 12th ed., (1996).
  • Therapeutic effect refers to a desired result which is achieved to some degree.
  • a number of desired results are referred to as “improving vaginal cell health.”
  • therapeutic effects may be achieved by delivering a non-systemic "effective amount" of a substance capable of achieving the desired result to a selected degree. While the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision.
  • vaginal dyspareunia is used throughout the specification to describe a symptom or condition of menopause wherein vaginal atrophy, dryness and pain during sexual intercourse occurs.
  • vaginal application means a composition in which the drug may be placed for direct application to the vaginal skin surface and from which an effective amount of drug is released.
  • topical formulations include but are not limited to ointments, creams, gels, sprays, vaginal rings, and pastes.
  • Vaginal administration can be accomplished by applying, pasting, rolling, attaching, pouring, pressing, rubbing, etc., of a topical preparation onto the vaginal skin surface. These and additional methods of administration are well-known in the art.
  • “Woman” refers to a human female who benefits from an androgen or estrogen administration in any way.
  • the female may be pre, peri or post menopausal due to age, oophorectomy, or ovarian failure.
  • the female may display a deficiency, or imbalance of the vaginal cells which may benefit from the topical non-systemic administration of an estrogen and/or androgenic hormone.
  • the present invention provides a method a method of treating sexual dysfunction in a human female which comprises administering directly to the vaginal tissue of a human female exhibiting one or more symptoms associated with a condition of sexual dysfunction and who is not receiving chronic hormonal therapy, prior to the female engaging in sexual intercourse, an effective sexual dysfunction treatment amount of at least one hormone selected from the group consisting of estrogen and androgen and/or pharmaceutically acceptable salt and ester thereof.
  • the pharmaceutical formulations of the invention will include at least one member selected from the group consisting of estrogen and androgen, or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
  • “Pharmaceutically acceptable salts, esters, or inclusion complexes” refer to those salts, esters and inclusion complexes ⁇ which retain the biological effectiveness and properties of the base compounds and which are not biologically or otherwise undesirable.
  • Salts, esters and inclusion complexes of the active agents may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992).
  • acid addition salts are prepared from the free base (typically wherein the neutral form of the drug has a neutral NH 2 group) using conventional means, involving reaction with a suitable acid.
  • Estrogens will generally be selected from the group consisting of, pharmaceutically acceptable salts and esters of any of the foregoing, and mixtures thereof.
  • such steroids include estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estriol, estrone, estrone benzoate, ethynyl estradiol, and mestranol, in the estrogen family, and acetoxypregnenolone, ethisterone, fluorogestone acetate.
  • an androgenic agent such as testosterone, dihydrotestosterone, testosterone analogues such as dehydroepiandrosterone (“DHEA”) and DHEA sulfate, or the like.
  • DHEA dehydroepiandrosterone
  • DHEA sulfate or the like.
  • the pharmaceutical formulations used in the methods of the present invention may also include one or more pharmacologically active agents other than the estrogen and androgen.
  • the formulations may contain a vasodilating agent.
  • vasodilating agents are naturally occurring prostaglandins or hydrolyzable lower alkyl esters of a naturally occurring prostaglandin, as well as other vasodilators known in the art.
  • the pharmaceutical formulations used in the methods of the present invention may also include one or more lubricants.
  • one or more lubricants selected from the group consisting of pullulan, ammonium poly(meth)acrylate, arabian gum, dextran, tamarindo gum, furcelieran, sodium starch-glycoUic acid, sodium polyacrylate, hyaluronic acid and polyvinyl pyrrolidone.
  • the pharmaceutical formulations used herein will typically contain one or more pharmaceutically acceptable carriers (also termed “excipients” or “vehicles”) suited to the particular type of formulation, i.e., gel, ointment, suppository, or the like.
  • the vehicles are comprised of materials of naturally occurring or synthetic origin that do not adversely affect the estrogen, androgen, vasodilating agent or other components of the formulation.
  • Suitable carriers for use herein include water, silicone, waxes, petroleum jelly, polyethylene glycol, propylene glycol, liposomes, sugars such as mannitol and lactose, and a variety of other materials, depending, again, on the specific type of formulation used.
  • compositions used herein may be in the form of an ointment, cream, emulsion, lotion, gel, solid, sprays, solution, suspension, foam or liposomal composition; such formulations may be used for clitoral, vulvar or vaginal delivery.
  • the compositions may be contained within a vaginal ring, tampon, suppository, sponge, pillow, puff, or osmotic pump system; these platforms are useful solely for vaginal delivery.
  • Methods for preparing various dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed. (Easton, Pa.: Mack Publishing Company, 1990).
  • Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives.
  • the specific ointment base to be used is one that will provide for optimum drug delivery.
  • an ointment base should be inert, stable, nonirritating and nonsensitizing.
  • ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases.
  • Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum.
  • Emulsifiable ointment bases also known as absorbent ointment bases, contain little or no welter and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum.
  • Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid.
  • Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy for further information.
  • Lotions are preparations that may be applied without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base.
  • Lotions are usually suspensions of solids, and preferably, for the present purpose, comprise a liquid oily emulsion of the oil-in- water type. It is generally necessary that the insoluble matter in a lotion be finely divided.
  • Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethyl-cellulose, or the like.
  • Pharmaceutical emulsion formulations are generally formed from a dispersed phase (e.g., a pharmacologically active agent), a dispersion medium and an emulsifing agent. If desired, emulsion stabilizers can be included in the formulation as well.
  • a dispersed phase e.g., a pharmacologically active agent
  • emulsion stabilizers can be included in the formulation as well.
  • a number of pharmaceutically useful emulsions are known in the art, including oil- in-water (o/w) formulations, water-in-oil (w/o) formulations and multiple emulsions such as w/o/w or o/w/o formulations.
  • Emulsifying agents suitable for use in such formulations include, but are not limited to, TWEEN 60®, Span 80®, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
  • Cream bases are water- washable, and contain an oil phase, an emulsifier and an aqueous phase.
  • the oil phase also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
  • the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant.
  • a typical gel composition is formulated by the addition of a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer to a solution.
  • a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer.
  • the preferred concentration of the gelling agent may range from 0.1 to 4 percent by weight of the total composition.
  • compositions used herein can further comprise one or more additional ingredients, such as one or more thickening agents, medicinal agents or pharmaceuticals, bioadhesive polymers, inert carriers, lipid absorbents, viscosity stabilizers, chelating agents, buffers, anti-fading agents, stabilizers, moisture absorbents, fragrances, colorants, film-forming materials, and refatting agents, etc.
  • additional ingredients such as one or more thickening agents, medicinal agents or pharmaceuticals, bioadhesive polymers, inert carriers, lipid absorbents, viscosity stabilizers, chelating agents, buffers, anti-fading agents, stabilizers, moisture absorbents, fragrances, colorants, film-forming materials, and refatting agents, etc.
  • additional excipients based on the physical and chemical properties desired in the final topical formulation. Of course, a single excipient may have multiple functions and properties.
  • Thickening agents are used to increase viscosity and improve bioadhesive properties.
  • the amount of thickening agent is preferably from about 1% to 10% by weight of the total composition weight, more preferably from about 2% to about 5% by weight.
  • Tissue penetration enhancers are contemplated herein, and are employed to improve the permeability of an active ingredient into the vaginal tissue and not into the patient's blood stream.
  • Penetration enhancers employed are those recognized in the art as safe for topical application to exposed tissue, for example one or more nonvolatile organic solvents such as, for example, amides, e.g., pyrrolidones; polyol ethers, e.g., glycol ethers; polyols, e.g., glycols, and derivatives thereof, etc.
  • the sexually therapeutic effective amount or sexually useful effective amount of the pharmaceutical formulation(s) disclosed herein should be administered from about 0.5 hours to about 8 hr prior to sexual activity. It is preferred that the pharmaceutical formulation be administered from about 15 minutes to about 1 hour prior to sexual activity. Most preferably, the pharmaceutical formulation is to be administered about 5 minutes to about 30 minutes prior to sexual activity.
  • Sexual activity includes sexual intercourse with or without orgasm, ejaculation, masturbation and sexual foreplay.
  • the amount of active agent administered is at least the minimum necessary to treat the dysfunction, e.g., excitement stage dysfunctions such as touch sensation impairment, loss of clitoral sensation, vaginal dryness, and concomitant dyspareunia.
  • the dysfunction e.g., excitement stage dysfunctions such as touch sensation impairment, loss of clitoral sensation, vaginal dryness, and concomitant dyspareunia.
  • estrogen and analogues thereof are administered at a level sufficient to exceed naturally occurring levels at the point of administration.
  • an amount of estrogen having estrogenic activity equivalent to from about 0.001 micrograms to about 100 micrograms ethinyl estradiol is applied directly to the vaginal tissue.
  • an applied dosage amount of estrogen having estrogenic activity equivalent to from about 0.01 micrograms to about 50 micrograms ethinyl estradiol is applied directly to the vaginal tissue.
  • an applied dosage amount of estrogen having estrogenic activity equivalent to from about 0.1 micrograms to about 35 micrograms ethinyl estradiol is applied directly to the vaginal tissue prior to sexual intercourse.
  • androgen and analogues thereof are administered in an amount having androgenic activity equivalent to from about 0.001 milligrams to about 3.00 milligrams methyltestosterone.
  • an applied dosage amount of androgen having androgenic activity equivalent from about 0.01 milligrams to about 2.0 milligrams methyltestosterone is applied directly to the vaginal tissue.
  • an applied dosage amount of androgen having androgenic activity equivalent to from about 0.1 milligrams to about 1.5 milligrams is applied directly to the vaginal tissue prior to sexual intercourse.
  • the use one or more vasodilator agents, as contemplated herein, are administered in a dosage that is at least the minimum necessary to treat the dysfunction.
  • One application unit is equivalent to one (1) gram of cream.
  • the application unit comprises 5 meg of ethenyl estradiol and 0.5mg of methyl testosterone.
  • One gram of cream has ⁇ the following composition: ethinyl estradiol 5 meg methyl testosterone 0.5mg
  • Polysorbate 60 (Tween 60) 15.0 mg
  • EXAMPLE 2 Suppository: Prepared by fusion or melt molding wherein one suppository unit comprises 15 meg of ethenyl estradiol and l.Omg of methyl testosterone.
  • One application unit is equivalent to one (1) gram of ointment.
  • the application unit comprises . 5 meg of ethenyl estradiol and 0.5mg of methyl testosterone.
  • One gram of ointment has the following composition: ethinyl estradiol 5.00 meg methyl testosterone 1.OOmg N-Methyl Pyrolidone
  • One application unit is equivalent to one (1) gram of gel.
  • the application unit comprises
  • HPMC Hydroxypropylmethylcellulose

Abstract

L’invention concerne des méthodes et des formules pour traiter le dysfonctionnement sexuel féminin. Une composition pharmaceutique pour l’administration non systémique topique est formulée afin de contenir un agent androgène et/ou oestrogène sélectionné administré au niveau de la région vaginale vulvaire de l’individu recevant le traitement.
PCT/US2006/002185 2005-05-24 2006-01-20 Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel WO2006127057A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68457405P 2005-05-24 2005-05-24
US60/684,574 2005-05-24

Publications (1)

Publication Number Publication Date
WO2006127057A1 true WO2006127057A1 (fr) 2006-11-30

Family

ID=36314061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002185 WO2006127057A1 (fr) 2005-05-24 2006-01-20 Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel

Country Status (1)

Country Link
WO (1) WO2006127057A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021805A2 (fr) * 2005-08-12 2007-02-22 Drugtech Corporation Compositions d'oestrogene et methodes d'utilisation a des fins therapeutiques
WO2008054214A2 (fr) * 2006-11-03 2008-05-08 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol éventuellement combiné à un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel
CN102552995A (zh) * 2010-12-07 2012-07-11 宁小静 人体润滑剂
US8227453B2 (en) 2004-05-11 2012-07-24 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2015138668A1 (fr) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Crème d'estradiol à faible dose
CN105055426A (zh) * 2015-07-23 2015-11-18 郭曙平 一种女性局部支持药物及其制备方法
US9333203B2 (en) 2005-11-11 2016-05-10 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034621A1 (fr) * 1997-02-07 1998-08-13 Theratech, Inc. Composition et procede servant a administrer testosterone a des femmes presentant des symptomes de deficience en testosterone
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030130244A1 (en) * 2001-11-09 2003-07-10 Bilkey Christopher R. Compositions for treatment of postmenopausal female sexual dysfunction
US20050059615A1 (en) * 2003-07-31 2005-03-17 Bodor Nicholas S. Transmucosal dosage forms for brain-targeted steroid chemical delivery systems

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034621A1 (fr) * 1997-02-07 1998-08-13 Theratech, Inc. Composition et procede servant a administrer testosterone a des femmes presentant des symptomes de deficience en testosterone
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030130244A1 (en) * 2001-11-09 2003-07-10 Bilkey Christopher R. Compositions for treatment of postmenopausal female sexual dysfunction
US20050059615A1 (en) * 2003-07-31 2005-03-17 Bodor Nicholas S. Transmucosal dosage forms for brain-targeted steroid chemical delivery systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOBO ROGERIO A ET AL: "Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire.", FERTILITY AND STERILITY, vol. 79, no. 6, June 2003 (2003-06-01), pages 1341 - 1352, XP002382020, ISSN: 0015-0282 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192669B2 (en) 2004-05-11 2015-11-24 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US10441592B2 (en) 2004-05-11 2019-10-15 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9700566B2 (en) 2004-05-11 2017-07-11 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US8227453B2 (en) 2004-05-11 2012-07-24 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2007021805A3 (fr) * 2005-08-12 2007-08-09 Drugtech Corp Compositions d'oestrogene et methodes d'utilisation a des fins therapeutiques
WO2007021805A2 (fr) * 2005-08-12 2007-02-22 Drugtech Corporation Compositions d'oestrogene et methodes d'utilisation a des fins therapeutiques
US9737548B2 (en) 2005-11-11 2017-08-22 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9333203B2 (en) 2005-11-11 2016-05-10 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9597335B2 (en) 2006-11-03 2017-03-21 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
US8669242B2 (en) 2006-11-03 2014-03-11 Emotional Brain B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
US8653051B2 (en) 2006-11-03 2014-02-18 Emotional Brain B.V. Use of 3-alpha-androstanediol in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction
US9211334B2 (en) 2006-11-03 2015-12-15 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
US8648060B2 (en) 2006-11-03 2014-02-11 Emotional Brain B.V. Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction
US8575139B2 (en) 2006-11-03 2013-11-05 Emotional Brain B.V. Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction
WO2008054214A3 (fr) * 2006-11-03 2009-04-09 Emotional Brain Bv Utilisation de 3-alpha-androstanediol éventuellement combiné à un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel
US10314848B2 (en) 2006-11-03 2019-06-11 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
WO2008054214A2 (fr) * 2006-11-03 2008-05-08 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol éventuellement combiné à un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel
CN102552995A (zh) * 2010-12-07 2012-07-11 宁小静 人体润滑剂
WO2015138668A1 (fr) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Crème d'estradiol à faible dose
AU2015229421B2 (en) * 2014-03-12 2020-06-04 Allergan Therapeutics LLC Low-dose estradiol cream
CN105055426A (zh) * 2015-07-23 2015-11-18 郭曙平 一种女性局部支持药物及其制备方法

Similar Documents

Publication Publication Date Title
US20090124584A1 (en) Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
US5877216A (en) Treatment of female sexual dysfunction
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
DE69434697T2 (de) Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose
EP1359920B1 (fr) UTILISATIONS DES FORMULATIONS ORALES POUR LE TRAITEMENT DEs DYSFONCTIONNEMENTS SEXUELS CHEZ LA FEMME
US7226910B2 (en) Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
AU2002245104B2 (en) Topical testosterone formulations and associated methods
EP2000143B1 (fr) Compositions transdermiques sous forme de gel contenant de la testostérone et leur utilisation dans le traitement de la fibromyalgie
US6432940B1 (en) Uses for androst-5-ene-3β, 17β-diol
US6228852B1 (en) Transdermal application of naturally occurring steroid hormones
US20060254597A1 (en) Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound
AU2002232759A1 (en) Methods and formulations for the treatment of female sexual dysfunction
WO2006127057A1 (fr) Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel
KR20050106508A (ko) 활성제들의 경피 또는 경점막 투여를 위한 용도들 및제제들
PT1322336E (pt) Método de aumentar as concentrações de testosterona e esteróides relacionados em mulheres
AU6265998A (en) Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
JP2008517952A (ja) 皮膚老化となる可能性を低下させるための、または皮膚老化を処置するためのアンドロゲンの使用
JP4920822B2 (ja) ステロイド性アロマターゼインヒビターを含有する乳癌の予防および／または治療薬
US20020187165A1 (en) Composition for female sexual arousal
RU2234920C2 (ru) Введение непероральным путем андрогенных стероидов женщинам

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06719148

Country of ref document: EP

Kind code of ref document: A1